Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 2/2020

01-04-2020 | Direct Oral Anticoagulant | Research Article

Risk of major bleeding in elderly patients with atrial fibrillation on direct oral anticoagulants: real world experience

Authors: Petra Šinigoj, Nina Vene, Katarina Košmelj, Alenka Mavri

Published in: International Journal of Clinical Pharmacy | Issue 2/2020

Login to get access

Abstract

Background The efficacy and safety of direct oral anticoagulants is well established in patients with atrial fibrillation. However, data on their use in the oldest old patients (≥ 85 years), who have the highest risk of bleeding, is scarce. Objective The aim of this study was to evaluate the safety of direct oral anticoagulants in the oldest old patients with atrial fibrillation and assess the impact of age on major bleeding events. Setting Anticoagulation Clinic of the Department of Vascular Diseases, University Medical Centre Ljubljana, Slovenia. Methods From our single-centre prospective registry we enrolled 2260 consecutive atrial fibrillation patients aged ≥ 65 years that were started on dabigatran, rivaroxaban or apixaban. The mean duration of treatment exposure was 735 days. The primary outcome was the incidence of major bleeding. The incidence of thromboembolic events and death were also assessed. Potential risk factors for major bleeding were evaluated using Cox regression analysis. Main outcome measure Rate of major bleeding. Results During the follow-up 106 patients experienced major bleeding (2.3%/year). The oldest old patients (≥ 85 years) had the highest risk of any major bleeding (HR 2.50, 95% CI 1.44–4.32, p = 0.001), intracranial bleeding (HR 4.74, 95% CI 1.48–15.14, p < 0.01) and major gastrointestinal bleeding (HR 2.32, 95% CI 1.10–4.89, p < 0.03) compared to the group of patients aged 65–74 years, even though the majority of them were treated with reduced doses of direct oral anticoagulants. Significant predictors for major bleeding were age group ≥ 85 years (HR 2.52, 95% CI 1.43–4.47, p = 0.001) and history of bleeding (HR 3.32, 95% CI 1.87–5.90, p < 0.001). The incidence of a composite of stroke, transient ischemic attack and systemic embolism was 1.3%/year. Conclusion In this prospective real-world clinical study we have shown that the oldest old patients have the highest risk of major bleeding, which is further increased with a patient’s history of bleeding.
Literature
1.
go back to reference Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the framingham study. Stroke. 1991;22(8):983–8.PubMedCrossRef Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the framingham study. Stroke. 1991;22(8):983–8.PubMedCrossRef
2.
go back to reference Björck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited. Stroke. 2013;44(11):3103–8.PubMedCrossRef Björck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited. Stroke. 2013;44(11):3103–8.PubMedCrossRef
3.
go back to reference Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015;4(1):e001486.PubMedPubMedCentralCrossRef Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015;4(1):e001486.PubMedPubMedCentralCrossRef
4.
go back to reference Saposnik G, Black SE, Hakim A, Fang J, Tu JV, Kapral MK. Age disparities in stroke quality of care and delivery of health services. Stroke. 2009;40(10):3328–35.PubMedCrossRef Saposnik G, Black SE, Hakim A, Fang J, Tu JV, Kapral MK. Age disparities in stroke quality of care and delivery of health services. Stroke. 2009;40(10):3328–35.PubMedCrossRef
5.
go back to reference Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962.PubMedCrossRef Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962.PubMedCrossRef
6.
go back to reference Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand J-P, Berge E, et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2017;103(4):307–14.PubMedCrossRef Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand J-P, Berge E, et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2017;103(4):307–14.PubMedCrossRef
7.
go back to reference Staerk L, Fosbøl EL, Gadsbøll K, Sindet-Pedersen C, Pallisgaard JL, Lamberts M, et al. Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: temporal trends 2011–2015 in Denmark. Sci Rep. 2016;6(1):31477.PubMedPubMedCentralCrossRef Staerk L, Fosbøl EL, Gadsbøll K, Sindet-Pedersen C, Pallisgaard JL, Lamberts M, et al. Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: temporal trends 2011–2015 in Denmark. Sci Rep. 2016;6(1):31477.PubMedPubMedCentralCrossRef
8.
go back to reference Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation. Circulation. 2011;123(21):2363–72.PubMedCrossRef Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation. Circulation. 2011;123(21):2363–72.PubMedCrossRef
9.
go back to reference Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism. Circulation. 2014;130(2):138–46.PubMedCrossRef Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism. Circulation. 2014;130(2):138–46.PubMedCrossRef
10.
go back to reference Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the Aristotle trial. Eur Heart J. 2014;35(28):1864–72.PubMedPubMedCentralCrossRef Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the Aristotle trial. Eur Heart J. 2014;35(28):1864–72.PubMedPubMedCentralCrossRef
11.
go back to reference Alexander JH, Andersson U, Lopes RD, Hijazi Z, Hohnloser SH, Ezekowitz JA, et al. Apixaban 5 mg twice daily and clinical outcomes in patients with atrial fibrillation and advanced age, low body weight, or high creatinine. JAMA Cardiol. 2016;1(6):673–81.PubMedCrossRef Alexander JH, Andersson U, Lopes RD, Hijazi Z, Hohnloser SH, Ezekowitz JA, et al. Apixaban 5 mg twice daily and clinical outcomes in patients with atrial fibrillation and advanced age, low body weight, or high creatinine. JAMA Cardiol. 2016;1(6):673–81.PubMedCrossRef
12.
go back to reference Fang MC, Go AS, Hylek EM, Chang Y, Henault LE, Jensvold NG, et al. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc. 2006;54(8):1231–6.PubMedPubMedCentralCrossRef Fang MC, Go AS, Hylek EM, Chang Y, Henault LE, Jensvold NG, et al. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc. 2006;54(8):1231–6.PubMedPubMedCentralCrossRef
13.
go back to reference Mant J, Hobbs FR, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the birmingham atrial fibrillation treatment of the aged study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493–503.PubMedCrossRef Mant J, Hobbs FR, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the birmingham atrial fibrillation treatment of the aged study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493–503.PubMedCrossRef
14.
go back to reference Lauw MN, Eikelboom JW, Coppens M, Wallentin L, Yusuf S, Ezekowitz M, et al. Effects of dabigatran according to age in atrial fibrillation. Heart. 2017;103(13):1015–23.PubMedCrossRef Lauw MN, Eikelboom JW, Coppens M, Wallentin L, Yusuf S, Ezekowitz M, et al. Effects of dabigatran according to age in atrial fibrillation. Heart. 2017;103(13):1015–23.PubMedCrossRef
15.
go back to reference Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–4.PubMedCrossRef Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–4.PubMedCrossRef
17.
go back to reference Nishida T, Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, et al. Oral anticoagulant use and clinical outcomes in elderly Japanese patients: findings from the SAKURA AF registry. Heart Vessels. 2019;34(12):2021–30.PubMedCrossRef Nishida T, Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, et al. Oral anticoagulant use and clinical outcomes in elderly Japanese patients: findings from the SAKURA AF registry. Heart Vessels. 2019;34(12):2021–30.PubMedCrossRef
18.
go back to reference Monelli M, Molteni M, Cassetti G, Bagnara L, De Grazia V, Zingale L, et al. Non-vitamin K oral anticoagulant use in the elderly: a prospective real-world study—data from the registry of patients on non-vitamin K oral anticoagulants (Regina). Vasc Health Risk Manag. 2019;15:19–25.PubMedPubMedCentralCrossRef Monelli M, Molteni M, Cassetti G, Bagnara L, De Grazia V, Zingale L, et al. Non-vitamin K oral anticoagulant use in the elderly: a prospective real-world study—data from the registry of patients on non-vitamin K oral anticoagulants (Regina). Vasc Health Risk Manag. 2019;15:19–25.PubMedPubMedCentralCrossRef
19.
go back to reference Poli D, Antonucci E, Ageno W, Bertù L, Migliaccio L, Martinese L, et al. Oral anticoagulation in very elderly patients with atrial fibrillation: results from the prospective multicenter START2-REGISTER study. PLoS ONE. 2019;14(5):e0216831.PubMedPubMedCentralCrossRef Poli D, Antonucci E, Ageno W, Bertù L, Migliaccio L, Martinese L, et al. Oral anticoagulation in very elderly patients with atrial fibrillation: results from the prospective multicenter START2-REGISTER study. PLoS ONE. 2019;14(5):e0216831.PubMedPubMedCentralCrossRef
20.
21.
go back to reference Lai CL, Chen HM, Liao MT, Lin TT. Dabigatran, rivaroxaban, and warfarin in the oldest adults with atrial fibrillation in taiwan. J Am Geriatr Soc. 2018;66(8):1567–74.PubMedCrossRef Lai CL, Chen HM, Liao MT, Lin TT. Dabigatran, rivaroxaban, and warfarin in the oldest adults with atrial fibrillation in taiwan. J Am Geriatr Soc. 2018;66(8):1567–74.PubMedCrossRef
22.
go back to reference Šinigoj P, Malmström RE, Vene N, Rönquist-Nii Y, Božič-Mijovski M, Pohanka A, et al. Dabigatran concentration: variability and potential bleeding prediction in ‘real-life’ patients with atrial fibrillation. Basic Clin Pharmacol Toxicol. 2015;117(5):323–9.PubMedCrossRef Šinigoj P, Malmström RE, Vene N, Rönquist-Nii Y, Božič-Mijovski M, Pohanka A, et al. Dabigatran concentration: variability and potential bleeding prediction in ‘real-life’ patients with atrial fibrillation. Basic Clin Pharmacol Toxicol. 2015;117(5):323–9.PubMedCrossRef
23.
go back to reference Miklič M, Mavri A, Vene N, Söderblom L, Božič-Mijovski M, Pohanka A, et al. Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation. Eur J Clin Pharmacol. 2019;75(8):1069–75.PubMedCrossRef Miklič M, Mavri A, Vene N, Söderblom L, Božič-Mijovski M, Pohanka A, et al. Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation. Eur J Clin Pharmacol. 2019;75(8):1069–75.PubMedCrossRef
24.
go back to reference Patti G, Pecen L, Lucerna M, Huber K, Rohla M, Renda G, et al. Net clinical benefit of non-vitamin K antagonist versus vitamin K antagonist anticoagulants in elderly patients with atrial fibrillation. Am J Med. 2019;132(6):749–57.e5.PubMedCrossRef Patti G, Pecen L, Lucerna M, Huber K, Rohla M, Renda G, et al. Net clinical benefit of non-vitamin K antagonist versus vitamin K antagonist anticoagulants in elderly patients with atrial fibrillation. Am J Med. 2019;132(6):749–57.e5.PubMedCrossRef
25.
go back to reference Giustozzi M, Vedovati MC, Verso M, Scrucca L, Conti S, Verdecchia P, et al. Patients aged 90 years or older with atrial fibrillation treated with oral anticoagulants: a multicentre observational study. Int J Cardiol. 2019;281:56–61.PubMedCrossRef Giustozzi M, Vedovati MC, Verso M, Scrucca L, Conti S, Verdecchia P, et al. Patients aged 90 years or older with atrial fibrillation treated with oral anticoagulants: a multicentre observational study. Int J Cardiol. 2019;281:56–61.PubMedCrossRef
26.
go back to reference Chao TF, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, et al. Oral anticoagulation in very elderly patients with atrial fibrillation: a nationwide cohort study. Circulation. 2018;138(1):37–47.PubMedCrossRef Chao TF, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, et al. Oral anticoagulation in very elderly patients with atrial fibrillation: a nationwide cohort study. Circulation. 2018;138(1):37–47.PubMedCrossRef
27.
go back to reference Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131(2):157–64.PubMedCrossRef Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131(2):157–64.PubMedCrossRef
28.
go back to reference De Caterina R, Andersson U, Alexander JH, Al-Khatib SM, Bahit MC, Goto S, et al. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the apixaban for reduction in stroke and Other thromboembolic events in atrial fibrillation trial. Am Heart J. 2016;175:175–83.PubMedCrossRef De Caterina R, Andersson U, Alexander JH, Al-Khatib SM, Bahit MC, Goto S, et al. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the apixaban for reduction in stroke and Other thromboembolic events in atrial fibrillation trial. Am Heart J. 2016;175:175–83.PubMedCrossRef
29.
go back to reference Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, Nessel CC, et al. Factors associated with major bleeding events. J Am Coll Cardiol. 2014;63(9):891–900.PubMedCrossRef Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, Nessel CC, et al. Factors associated with major bleeding events. J Am Coll Cardiol. 2014;63(9):891–900.PubMedCrossRef
Metadata
Title
Risk of major bleeding in elderly patients with atrial fibrillation on direct oral anticoagulants: real world experience
Authors
Petra Šinigoj
Nina Vene
Katarina Košmelj
Alenka Mavri
Publication date
01-04-2020
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 2/2020
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-020-01008-1

Other articles of this Issue 2/2020

International Journal of Clinical Pharmacy 2/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.